106973-36-8

Usage

Uses

Used in Pharmaceutical Industry:
(R)-4-Benzyl-5-oxo-3-morpholinecarboxylic Acid is used as a key intermediate for the synthesis of various pharmaceuticals and biologically active molecules. Its unique structure and chirality make it a valuable building block for the development of new drugs with improved efficacy and selectivity.
Used in Chemical Synthesis:
(R)-4-Benzyl-5-oxo-3-morpholinecarboxylic Acid is used as a versatile building block in organic synthesis, particularly for the preparation of enantiomerically pure compounds. Its ability to be synthesized from serine enantiomers and the reduction of 5-oxomorpholine-3-carboxylates makes it an attractive candidate for the development of novel chiral molecules with potential applications in various fields.
Used in Research and Development:
(R)-4-Benzyl-5-oxo-3-morpholinecarboxylic Acid is used as a research tool for studying the structure-activity relationships of various biologically active molecules. Its unique structure and synthetic accessibility make it an ideal candidate for exploring the effects of different functional groups and stereochemistry on the biological activity of target molecules.

InChI:InChI=1/C12H13NO4/c14-11-8-17-7-10(12(15)16)13(11)6-9-4-2-1-3-5-9/h1-5,10H,6-8H2,(H,15,16)/t10-/m1/s1

Upstream product

• 100-52-7 benzaldehyde 
• 79-04-9 chloroacetyl chloride 
• 515156-88-4 N-benzyl-D-serine 
• 1007169-00-7 (R)-2-(N-benzyl-2-chloroacetamido)-3-hydroxypropanoic acid 
• 106910-77-4 N-(phenylmethyl)-D-serine 

Downstream Products

• 106973-39-1 ethyl (R)-4-benzyl-5-oxomorpholine-3-carboxylate 
• 106910-85-4 ethyl (R)-4-benzylmorpholine-3-carboxylate 
• 1089280-09-0 (3R)-5-oxo-N,4-bis(phenylmethyl)-3-morpholinecarboxamide 
• 1268364-45-9 (7S,9aS)-7-[(benzyloxy)methyl]octahydropyrazino[2,1-c][1,4]oxazine 
• 1268364-48-2 [(S)-1-benzyloxymethyl-2-((S)-3-hydroxymethyl-morpholin-4-yl)-ethyl] carbamic acid tert-butyl ester 
• 1268364-49-3 [(S)-1-benzyloxymethyl-2-((R)-3-chloromethyl-morpholin-4-yl)-ethyl] carbamic acid tert-butyl ester 
• 1268364-50-6 (S)-1-benzyloxymethyl-2-((R)-3-chloromethyl-morpholin-4-yl)ethylamine 
• 211053-50-8 (S)-3-(hydroxymethyl)morpholine 
• 1152107-25-9 GSK1322322 
• 1152110-20-7 [(2R)-2-(cyclopentylmethyl)-3-(2-{5-fluoro-6-[(9aS)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-2-methyl-4-pyrimidinyl}hydrazino)-3-oxopropyl][(phenylmethyl)oxy]formamide 
• 1126432-04-9 (9aS)-1,3,4,6,7,8,9,9a-octahydropyrazino[2,1-c][1,4]oxazine dihydrochloride 
• 1089280-13-6 (9aS)-8-(phenylmethyl)octahydropyrazino[2,1-c][1,4]oxazine 
• 1089280-11-4 (9aS)-8-(phenylmethyl)hexahydropyrazino[2,1-c][1,4]oxazine-6,7-dione 
• 1089280-12-5 ethyl oxo((phenylmethyl){[(3S)-4-(phenylmethyl)-3-morpholinyl]methyl}amino)acetate 

Relevant academic research and scientific papers

A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor

The mechanistic target of rapamycin (mTOR) plays a pivotal role in growth and tumor progression and is an attractive target for cancer treatment. ATP-competitive mTOR kinase inhibitors (TORKi) have the potential to overcome limitations of rapamycin derivatives in a wide range of malignancies. Herein, we exploit a conformational restriction approach to explore a novel chemical space for the generation of TORKi. Structure-activity relationship (SAR) studies led to the identification of compound 12b with a ～450-fold selectivity for mTOR over class I PI3K isoforms. Pharmacokinetic studies in male Sprague Dawley rats highlighted a good exposure after oral dosing and a minimum brain penetration. CYP450 reactive phenotyping pointed out the high metabolic stability of 12b. These results identify the tricyclic pyrimido-pyrrolo-oxazine moiety as a novel scaffold for the development of highly selective mTOR inhibitors for cancer treatment.

PEPTIDE DEFORMYLASE INHIBITORS

The present invention relates to {2-(alkyl)-3-[2-(5-fluoro-4-pyrimidinyl)hydrazino]-3- oxopropyl}hydroxyformamide compounds of Formula (I): or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds in the inhibition of bacterial peptide deformylase (PDF) activity and in treatment methods for bacterial infections

ANHYDRATE FORMS OF A PYRIDINE DERIVATIVE

The invention relates to the compound of formula (I) in a crystalline anhydrate form, pharmaceutical formulations containing them, their use in therapy and processes for preparing the same.

Fused Thiazole Derivatives As Kinase Inhibitors

A series of 6,7-dihydro[1,3]thiazolo[5,4-c]pyridin-4(5H)-one derivatives, which are substituted in the 2-position by a substituted morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.

PEPTIDE DEFORMYLASE INHIBITORS

The present invention is directed to certain {2-(alkyl)-3-[2-(5-fluoro-4-pyrimidinyl)hydrazino]-3-oxopropyl}hydroxyformamide derivatives, compositions containing them, the use of such compounds in the inhibition of bacterial peptide deformylase (PDF) activity, and in the treatment of bacterial infections. Specifically, the invention is directed to compounds of formula (I), wherein R1, R2 and R3 are defined herein and to pharmaceutically acceptable salts thereof. The compounds of this invention are bacterial peptide deformylase inhibitors and can be useful in the treatment of bacterial infections.

FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS

A series of fused bicyclic thiazole and thiophene derivatives which are substituted in the 2-position by an optionally substituted morpholin-4-yl moiety, and in the 4-position by hydroxy, oxo or an amine moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. (I)

2-AMINOBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS

Compounds of formulae I, II and III: are disclosed as 5-HT3 inhibitors. The compounds are useful in treating CINV, IBS-D and other diseases and conditions.

Imidazopyridine Kinase Inhibitors

The present invention provides imidazopyridine compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.

THIAZOLE DERIVATIVES AS KINASE INHIBITORS

A series of thiazole derivatives which are substituted in the 2-position by a substituted morpholin-4-yl moiety, being selective inhibitors of P13 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.

FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS

A series of 6,7-dihydro[1,3]thiazolo[5,4-c]pyridin-4(5H)-one derivatives, which are substituted in the 2-position by a substituted morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.